Home | News | Directories | Calendar | Maps | Contact Us | Webmail
Penn Medicine Advanced Search

Aimee S. Payne, MD,PhD

Aimee S. Payne, MD,PhD

faculty photo
Professor of Dermatology
Department: Dermatology
Graduate Group Affiliations

Contact information
1009 Biomedical Research Building
421 Curie Boulevard
Philadelphia, PA 19104
Office: 215-662-2737
Fax: 215-573-2143
Lab: 215-898-3232
Education:
BS (Biology)
Stanford University, 1993.
MD, PhD (Molecular and Cellular Biology)
Washington University School of Medicine, 2001.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Research Interests:
Precision cellular immunotherapies for B cell-mediated diseases
Genetic and functional characterization of human anti-desmoglein B cell repertoires

Key words: autoimmunity, human immunology, CAR T cells, cell therapy, precision medicine, dermatology, skin, B cell

Description of Research:
Autoimmune disease occurs when the immune system mistakenly attacks healthy tissues, leading to organ damage. Pemphigus vulgaris is a potentially fatal disorder in which autoantibodies against desmosomal cell adhesion molecules known as desmogleins cause blistering of the skin and mucous membranes. Our laboratory is interested in better understanding pathogenic mechanisms in this model organ-specific autoimmune disease, from both the immunologic and cell biologic perspectives, and to use our knowledge of disease to develop better targeted therapies for a broad range of B-cell mediated autoimmune diseases.

A fundamental question in organ-specific autoimmune disease is why the immune system breaks tolerance against only a limited number of self-antigens. We have cloned B cell repertoires from pemphigus vulgaris patients to understand how they developed desmoglein autoreactivity. We identified shared VH1-46 gene usage in anti-desmoglein 3 B cells from different pemphigus patients and defined acidic amino acid residues that are necessary and sufficient to confer desmoglein 3 autoreactivity. We also identified common as well as divergent features of the B cell response to the self-antigen desmoglein 3 and the rotavirus VP6 antigen. Our studies indicate shared VH gene usage in the immune response to foreign and self antigens as a potential basis for triggering pathologic autoimmune reactions, but divergent evolution limits the onset of autoimmunity after infection. Further studies have uncovered the developmental pathways and lineage relationships of IgG and IgA B cells in pemphigus, indicating that the IgG4 B cells that are predominant in active disease are clonally distinct from the more clonally interrelated IgG1-IgA1-IgA2 axis.

Our laboratory has also elucidated the cell regulatory pathways that promote desmosome adhesion. We have shown that the p38 MAPK/MK2 axis governs keratinocyte desmosomal adhesion and that inhibition of this pathway can ameliorate pemphigus skin blistering. We identified STAT3 as a key regulator of desmoglein 3 transcription in keratinocytes, which contributes to the rapid therapeutic effect of corticosteroids in pemphigus and may explain the loss of desmoglein 3 expression in advanced head and neck squamous cell cancers.

Ultimately, a better understanding of the shared structural elements of autoreactive B cell repertoires can lead to better targeted therapies for disease. Current methods for treating autoimmunity require general immune suppression to reduce antibody production, but this approach impairs protective immune responses, which can lead to potentially fatal infections and secondary cancers. We described a novel method for re-engineering chimeric antigen receptor (CAR) T cells, which have led to lasting remissions of B cell-mediated cancers, for precision cellular immunotherapy of B cell-mediated autoimmune diseases such as pemphigus vulgaris. By using the pemphigus autoantigen desmoglein 3 as the extracellular domain of a chimeric autoantibody receptor (CAAR), we can direct a patient’s T cells to specifically seek out and kill the pemphigus-specific B cells, while sparing healthy B cells. We published initial proof-of-concept for the CAAR approach as well as the definitive preclinical studies that enabled an Investigational New Drug application for DSG3-CAART, which is now in a phase 1 trial to determine safety and preliminary efficacy of this approach. In addition, we have extended the CAAR concept to other B cell-mediated diseases, including muscle-specific tyrosine kinase (MuSK) myasthenia gravis, which is being evaluated in a phase 1 clinical trial, and phospholipase A2 receptor (PLA2R) membranous nephropathy. We are also collaborating with Dr. Nicola Mason at Penn Vet to apply these technologies to the treatment of dogs with cancer and autoimmune conditions.

Lab personnel:
Casey Lee, MD-PhD graduate student
Emma Goodman, graduate student
Silvio Manfredo-Vieira, PhD, Assistant Director, Correlative and Translational Studies
Xuming Mao, MD, PhD, senior research investigator
Damian Maseda, PhD, senior research investigator
Sangwook Oh, PhD, senior research investigator
Burcin Altun, PhD, senior research investigator
Insuk Choe, JD, program coordinator
Eun Jung Choi, MS, lab manager

Lab alumni (current position):
Takeru Funakoshi, MD, PhD (Dermatology faculty, Keio University, Japan)
Arielle Nagler, MD (Assistant Professor and Medical Director, New York University)
Sara Berg, MD (Dermatology, Lahey Hospital and Medical Center, Tufts University School of Medicine)
Nina Ran, MD, MTR (Dermatology instructor, Brigham and Women’s Hospital)
Michael Jeffrey Cho, PhD (Senior Manager, GlaxoSmithKline)
Eric Mukherjee, MD, PhD (Dermatology instructor, Vanderbilt University)
Napatra Tovanabutra, MD (Dermatology faculty, Chiang Mai University, Thailand)
Baomei Wang, PhD (Principal Scientific Researcher, Genentech)
Jinmin Lee, PhD (Associate Principal Scientist, Cabaletta Bio)
Christoph Ellebrecht, MD, tenure-track assistant professor (Penn)

Other Penn and non-Penn Appointments:
Co-Director, Dermatology Research Residency Program, Penn
Faculty Advisor, Association for Women Student MD-PhDs (AWSM), Penn
Medical Advisory Council, International Pemphigus and Pemphigoid Foundation
Chair, NIAMS Board of Scientific Counselors
Vice President, Society for Investigative Dermatology

Description of Clinical Expertise

Medical Dermatology
Blistering Skin Diseases

Selected Publications

Oh S, Mao X, Manfredo-Vieira S, Lee J, Patel D, Choi EJ, Alvarado A, Cottman-Thomas E, Maseda D, Tsao PY, Ellebrecht CT, Khella SL, Richman DP, O’Connor KC, Herzberg U, Binder GK, Milone MC, Basu S, Payne AS: Precision targeting of autoantigen-specific B-cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T-cells. Nature Biotechnol in press, 2023.

Tovanabutra N, Bax CE, Feng R, Kushner CJ, Payne AS: Temporal outcomes after rituximab therapy for pemphigus. J. Invest. Dermatol. 142(4): 1058-1064, 2022 Notes: doi:10.1016/j.jid.2021.09.013.

Lee J, Lundgren DK, Mao X, Manfredo-Vieira S, Nunez-Cruz S, Williams EF, Assenmacher CA, Radaelli E, Oh S, Wang B, Ellebrecht CT, Fraietta JA, Milone MC, Payne AS: Antigen specific B-cell depletion for precision therapy of mucosal pemphigus vulgaris. J Clin Invest 130(12): 6317-6324, 2020 Notes: doi:10.1172/JCI13841.

Maehara T, Kaneko N, Perugino CA, Mattoo H, Kers J, Allard-Chamard H, Mahajan VS, Liu H, Murphy SJ, Ghebremichael M, Fox DA, Payne AS, Lafyatis R, Stone JH, Khanna D, Pillai S: Cytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosis. J Clin Invest 130(5): 2451-2464, Jan 2020 Notes: https://doi.org/10.1172/JCI131700.

Kushner CJ, Wang S, Tovanabutra N, Tsai DE, Werth VP, Payne AS: Factors associated with complete remission after rituximab therapy for pemphigus. JAMA Dermatol 155(12): 1404-09, 2019 Notes: doi:10.1001/jamadermatol.2019.3236.

Cho A, Caldara AL, Ran NA, Menne Z, Kauffman RC, Affer M, Llovet A, Norwood C, Scanlan A, Mantus G, Bradley B, Zimmer S, Schmidt T, Hertl M, Payne AS, Feldman R, Kowalczyk AP, Wrammert J : Single-cell analysis suggests that ongoing affinity maturation drives the emergence of pemphigus vulgaris autoimmune disease. Cell Rep 28(4): 909-922, Jul 23 2019.

Ellebrecht CT, Mukherjee EM, Zheng Q, Choi EJ, Reddy SG, Mao X, Payne AS: Autoreactive IgG and IgA B cells evolve through distinct subclass switch pathways in the autoimmune disease pemphigus vulgaris. Cell Rep 24(9): 2370-2380, Aug 28 2018.

Mao X, Cho MJ, Ellebrecht CT, Mukherjee EM, Payne AS: Stat3 regulates desmoglein 3 transcription in epithelial keratinocytes. JCI Insight 2(9): e92253, May 4 2017.

Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X, Cho MJ, Di Zenzo G, Lanzavecchia A, Seykora JT, Cotsarelis G, Milone MC, Payne AS: Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 353(6295): 179-184, Jul 8 2016.

Cho MJ, Lo ASY, Mao X, Nagler AR, Ellebrecht CT, Mukherjee EM, Hammers CM, Choi EJ, Sharma PM, Uduman M, Li H, Rux AH, Farber SA, Rubin CB, Kleinstein SH, Sachais BS, Posner MR, Cavacini LA, Payne AS: Shared VH1-46 gene usage by pemphigus vulgaris autoantibodies indicates common humoral immune responses among patients. Nature Commun 5: 4167, Jun 19 2014.

back to top
Last updated: 05/22/2023
The Trustees of the University of Pennsylvania